MNMD vs. BTMD, ACB, USNA, CDXC, CGC, MDWD, CRON, ITOS, STOK, and EXAI
Should you be buying Mind Medicine (MindMed) stock or one of its competitors? The main competitors of Mind Medicine (MindMed) include biote (BTMD), Aurora Cannabis (ACB), USANA Health Sciences (USNA), ChromaDex (CDXC), Canopy Growth (CGC), MediWound (MDWD), Cronos Group (CRON), iTeos Therapeutics (ITOS), Stoke Therapeutics (STOK), and Exscientia (EXAI). These companies are all part of the "medical" sector.
Mind Medicine (MindMed) (NASDAQ:MNMD) and biote (NASDAQ:BTMD) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their profitability, dividends, community ranking, institutional ownership, risk, earnings, valuation, media sentiment and analyst recommendations.
27.9% of Mind Medicine (MindMed) shares are held by institutional investors. Comparatively, 21.7% of biote shares are held by institutional investors. 2.1% of Mind Medicine (MindMed) shares are held by company insiders. Comparatively, 13.9% of biote shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
Mind Medicine (MindMed) has a beta of 2.72, suggesting that its share price is 172% more volatile than the S&P 500. Comparatively, biote has a beta of 0.87, suggesting that its share price is 13% less volatile than the S&P 500.
biote has higher revenue and earnings than Mind Medicine (MindMed). Mind Medicine (MindMed) is trading at a lower price-to-earnings ratio than biote, indicating that it is currently the more affordable of the two stocks.
Mind Medicine (MindMed) received 23 more outperform votes than biote when rated by MarketBeat users. However, 100.00% of users gave biote an outperform vote while only 90.00% of users gave Mind Medicine (MindMed) an outperform vote.
Mind Medicine (MindMed) currently has a consensus target price of $17.67, suggesting a potential upside of 114.92%. biote has a consensus target price of $8.11, suggesting a potential upside of 41.04%. Given Mind Medicine (MindMed)'s higher probable upside, research analysts plainly believe Mind Medicine (MindMed) is more favorable than biote.
biote has a net margin of 4.30% compared to Mind Medicine (MindMed)'s net margin of 0.00%. biote's return on equity of -36.67% beat Mind Medicine (MindMed)'s return on equity.
In the previous week, Mind Medicine (MindMed) had 9 more articles in the media than biote. MarketBeat recorded 17 mentions for Mind Medicine (MindMed) and 8 mentions for biote. biote's average media sentiment score of 0.68 beat Mind Medicine (MindMed)'s score of 0.45 indicating that biote is being referred to more favorably in the news media.
Summary
biote beats Mind Medicine (MindMed) on 10 of the 16 factors compared between the two stocks.
Get Mind Medicine (MindMed) News Delivered to You Automatically
Sign up to receive the latest news and ratings for MNMD and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding MNMD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Mind Medicine (MindMed) Competitors List
Related Companies and Tools
